Hexarelin: Evidence, Mechanism, Dosing & Legal Status

Hexarelin (examorelin; sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic hexapeptide growth-hormone secretagogue marketed in fitness and longevity circles for GH release, fat loss and "cardioprotection."1 What separates it from most research peptides is that some of those claims actually have human data behind them — and others clearly do not. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Hexarelin is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is hexarelin and how does it work?

Hexarelin is a synthetic hexapeptide; the D-2-methyl-tryptophan substitution confers metabolic stability and resistance to enzymatic degradation, making it more chemically stable and functionally more potent than endogenous ghrelin at their shared receptor.18 Unusually, it acts at two distinct receptors, which is the key to understanding both its proven and its unproven effects.

The first target is GHS-R1a, the ghrelin receptor — the Gq/phospholipase-C-coupled GPCR that mediates pituitary GH release. Because GHRH signals through a separate cAMP-dependent receptor, low-dose hexarelin combined with GHRH is synergistic, producing far greater GH release than either alone, and hexarelin also acts at the hypothalamic level by promoting GHRH tone and antagonizing somatostatin.1 The second target is CD36, a scavenger receptor expressed on cardiomyocytes, microvascular endothelium, monocytes and adipocytes; photoaffinity mapping localized the binding domain to CD36 residues Asn132-Glu177, overlapping the oxidized-LDL binding site, and CD36 signaling (Src kinases, FAK, PI3K/AKT, PPAR) is the proposed basis for hexarelin's GH-independent cardiovascular and metabolic actions.78 Ghrelin itself binds CD36 only weakly — a key distinction.

In the human dose-response study, plasma GH rose dose-dependently, peaked at about 30 minutes and returned to baseline within roughly 240 minutes, with a GH-response half-life near 55 minutes; animal plasma half-life is about 76 minutes in rats and 120 minutes in dogs.115 The full receptor and clinical-trial context can be cross-checked against the public literature index at PubMed.

What is the evidence by indication?

Hexarelin's evidence is genuinely tiered: two human uses reach Grade B, while the claims that dominate marketing remain animal-grade. The table below grades each indication honestly.

The best human data are for GH provocation. In the foundational double-blind, placebo-controlled, rising-dose study, 12 healthy men received IV boluses of 0.5, 1 and 2 µg/kg versus placebo; mean peak GH was 3.9, 26.9, 52.3 and 55.0 ng/mL respectively, with the 2 µg/kg dose approaching the maximal response.1 Combined hexarelin plus GHRH has been proposed as an alternative to the insulin tolerance test for diagnosing GH deficiency, with high sensitivity and specificity in cited series — though hexarelin itself was never approved as a diagnostic agent (macimorelin later filled that niche).1213

The second Grade-B use is acute cardiac performance. In 24 male CAD patients undergoing bypass surgery, IV hexarelin produced prompt increases in left-ventricular ejection fraction, cardiac index and cardiac output (all P<0.001) lasting to 90 minutes, with reduced wedge pressure and no change in systemic vascular resistance or heart rate. Critically, recombinant human GH, GHRH and placebo produced no hemodynamic effect — indicating the cardiotropic effect is GH-independent, via cardiovascular CD36/GHS receptors.6 The benefit appeared in ischemic but not dilated cardiomyopathy — a meaningful stratification. This is genuinely promising human data, but it is acute, small-sample, surrogate-endpoint evidence with no outcome trial.

The cardioprotection and body-composition stories are where evidence thins. Hexarelin pretreatment protected GH-deficient rat hearts against ischemia-reperfusion injury via cardiac CD36, preserved myocardial function and reduced fibrosis after MI, and improved dyslipidemia and glucose tolerance in insulin-resistant mice — consistent, mechanistically coherent, but animal-grade.7109 In humans, GHS administration reliably raises GH and IGF-1 short-term, but few studies measure clinically meaningful endpoints such as body composition or function.14 The fat-loss framing is not supported by human efficacy trials.

What doses appear in the literature?

Reported strictly as information, not a protocol. For acute GH provocation and diagnostics, single IV boluses of 0.5, 1 or 2 µg/kg were used, with the 2 µg/kg dose approaching the maximal GH response; combined GH-axis testing used roughly 1 µg/kg IV with GHRH.112 The chronic-dosing human study used 1.5 µg/kg subcutaneously twice daily for 16 weeks in healthy elderly subjects — the regimen that characterized desensitization and HPA safety.23 A small pediatric IGF-1 study used 60 µg/kg intranasally three times daily in a research setting.12 Hexarelin is active by IV (most pharmacology and diagnostic work), subcutaneous, intranasal and oral routes, with oral and intranasal bioavailability lower than parenteral.1 Because continuous daily exposure attenuates the response, intermittent or cycled exposure is discussed in the literature as a way to preserve responsiveness.5 No approved human formulation, label or pharmacy-grade product exists.

How safe is hexarelin?

The best-characterized acute effect is endocrine spillover: hexarelin causes slight, transient increases in prolactin, cortisol and ACTH, while LH, FSH, TSH, glucose and IGF-1 are unaffected by acute dosing.1 The defining chronic concern is tachyphylaxis — over 16 weeks of 1.5 µg/kg SC twice daily, the AUC-GH fell from 19.1 to 10.5 µg/L·h, but the effect was partial and reversible, returning to baseline (19.4) four weeks after stopping.2 Reassuringly, that same chronic study found no sustained over-stimulation of the pituitary-adrenal axis or prolactin: basal cortisol and 24-hour urinary free cortisol were unchanged.3 Higher body-fat mass markedly blunts the GH response — a pharmacodynamic limitation rather than a toxicity.4

Theoretical risks include growth-promotion of occult or active malignancy via the GH/IGF-1 axis (a class caution, not a documented hexarelin signal) and unpredictable CD36-mediated cardiometabolic effects — CD36 is central to foam-cell formation, and hexarelin competes with oxidized LDL at CD36, which preclinically reduced atherosclerotic lesions but could cut either way in humans.8 Pregnancy, lactation and pediatric use outside research are precautionary contraindications. In practice, because no approved formulation exists, research-chemical hexarelin carries real purity, sterility and concentration hazards.18

What is the FDA and WADA status in 2026?

Hexarelin is not FDA-approved for any therapeutic or diagnostic indication.18 As a class, GH-secretagogue peptides were swept into Category 2 of the FDA's interim 503A bulks list — substances raising significant safety concerns, ineligible for compounding — in the September 2023 action; related GHRPs such as ipamorelin were reviewed at the October 2024 PCAC meeting with the FDA recommending against inclusion, and a further PCAC meeting on additional peptides was scheduled for July 23-24, 2026.1920 Hexarelin is not on any Category-1 permitted bulks list for 503A or 503B and is not legitimately compoundable as of 2026; it is sold only as a non-human research chemical, and clinical development (GHD diagnosis, cardiac indications) was discontinued.18

For athletes the picture is unambiguous. Hexarelin is prohibited at all times, explicitly named as "examorelin (hexarelin)" among GH-releasing peptides under section S2.2.4 of the 2026 WADA Prohibited List, which took effect January 1, 2026.1617 Modern LC-MS/MS methods can detect hexarelin and its metabolites, though the detection window is short. It is not a DEA-controlled substance.

Bottom line. Hexarelin is real, mechanistically fascinating science: a uniquely potent dual GHS-R1a/CD36 ligand with credible acute human cardiac data not reproduced by GHRH or recombinant GH, and well-characterized GH pharmacology — Grade B for its two genuine human uses, Grade C for the cardioprotection and body-composition claims that dominate marketing. From a functional, root-cause standpoint, the honest framing is that hexarelin is a potent investigational probe of the GH/ghrelin-CD36 axis with intriguing but unfinished human evidence — not a validated therapy. Regulatory facts here are current as of June 2026; the July 23-24, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.